Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 52

Sort by

Sort Order Select

Journal Articles

Intraindividual Comparison of Recognition of Symptom Burden in MPN between Patient- and Physician-Reported Assessment and Its Impact on Survival - an Analysis By the German Study Group for MPN (GSG-MPN)

Blood (2024) 144 (Supplement 1): 406.

https://doi.org/10.1182/blood-2024-206143

Published: 2024

Journal Articles

Firstline Treatment with Ruxolitinib Versus Best Available Therapy in Patients with Polycythemia Vera: Pre-Specified Interim Analysis of the Randomized Phase 2b Ruxobeat Clinical Trial of the German Study Group for Myeloproliferative Neoplasms (GSG-MPN)

Blood (2023) 142 (Supplement 1): 619.

https://doi.org/10.1182/blood-2023-173225

Published: 2023

Journal Articles

Decider-2: Prospective Randomized Multicenter Phase III Trial of Decitabine and Venetoclax Administered in Combination with All- Trans Retinoic Acid (ATRA) or Placebo in Patients with Acute Myeloid Leukemia Who Are Ineligible for Induction Chemotherapy

Michael Lübbert, Claudia Schmoor, Olga Grishina, Christoph Rummelt, Johanna Thomas, Michael Heuser, Konstanze Döhner, Hartmut Döhner, Heiko Becker, Ralph Wäsch

Blood (2023) 142 (Supplement 1): 1495.

https://doi.org/10.1182/blood-2023-181871

Published: 2023

Journal Articles

Single-Center Experience of Decitabine/Venetoclax in Newly Diagnosed Older AML Patients with Non-Favorable Genetics: Bridging to Allo-HCT or Treatment Continuation

David Alber, Christoph Rummelt, Tim Strüßmann, Andrés Rettig, Valeria Shlyakhto, Paul La Rosée, Martin Henkes, Elizaveta Bubnova, Tobias Ma, Johanna Thomas, Gabriele Ihorst, Claudia Wehr, Reinhard Marks, Heiko Becker, Justus Duyster, Ralph Wäsch, Jürgen Finke, Michael Lübbert

Blood (2023) 142 (Supplement 1): 7091.

https://doi.org/10.1182/blood-2023-187581

Published: 2023

Journal Articles

Siremadlin, a Human Double Minute-2 (HDM2) Inhibitor, Added to Ruxolitinib after Suboptimal Response to Ruxolitinib Alone in Patients with Myelofibrosis: Results from Part 1 of the Phase 1/2 Adore Study

Blood (2022) 140 (Supplement 1): 590–593.

https://doi.org/10.1182/blood-2022-158501

Published: 2022

Journal Articles

Genetic and Epigenetic Changes at Secondary Resistance after Continued Treatment in the Randomized Phase II Study of All- Trans Retinoic Acid (ATRA) and/or Valproic Acid (VPA) Added to Decitabine (DAC) in Newly Diagnosed Elderly AML Patients (DECIDER Trial)

Inga Hund, Maria Hess, Julia Stomper, Gabriele Greve, Jan Mitschke, Christoph Niemöller, Tobias Ma, David Uhl, Felicitas R. Thol, Michael Heuser, Gesine Bug, Martina Crysandt, Lutz Peter Mueller, Andreas Neubauer, Justus Duyster, Hartmut Dohner, Melanie Boerries, Heiko Becker, Michael Luebbert

Blood (2022) 140 (Supplement 1): 3383–3384.

https://doi.org/10.1182/blood-2022-163220

Published: 2022

Journal Articles

All- Trans retinoic Acid Enhances the Antileukemic Activity of Decitabine and Venetoclax in Non-M3 AML Cells

Helena Bresser, Usama-Ur Rehman, Julia Schüler, Anne Rubarth, Tobias Ma, Gabriele Greve, Heiko Becker, Michael Lübbert

Blood (2022) 140 (Supplement 1): 11537–11539.

https://doi.org/10.1182/blood-2022-167743

Published: 2022

Journal Articles

Ruxolitinib Versus Best Available Therapy in Patients with Essential Thrombocythemia: Pre-Specified Interim Analysis of the Randomized Phase 2b Ruxobeat Clinical Trial of the German Study Group for Myeloproliferative Neoplasms (GSG-MPN)

Blood (2022) 140 (Supplement 1): 1790–1793.

https://doi.org/10.1182/blood-2022-157265

Published: 2022

Journal Articles

Randomized Phase II Study of All- Trans Retinoic Acid and Valproic Acid Added to Decitabine in Newly Diagnosed Elderly AML Patients (DECIDER trial): Predictive Impact of TP53 Status

Blood (2021) 138 (Supplement 1): 2380.

https://doi.org/10.1182/blood-2021-146468

Published: 2021

Journal Articles

Activity of Decitabine (DAC) Combined with All-Trans Retinoic Acid (ATRA) in Oligoblastic AML: Subgroup Analysis of a Randomized 2x2 Phase II Trial

Blood (2020) 136 (Supplement 1): 9–10.

https://doi.org/10.1182/blood-2020-140664

Published: 2020

Journal Articles

Clinical Relevance of Somatic Mutations in Chronic Myelomonocytic Leukemia Undergoing Allogeneic Stem Cell Transplantation

Nico Gagelmann, Anita Badbaran, Rashit Bogdanov, PhD, Olivier Nibourel, Friedrich Stoelzel, MD, Christina Rautenberg, MD, Heiko Becker, MD, Aleksandar Radujkovic, MD, Michael Koldehoff, Prof, MD PhD, Maximilian Christopeit, PhD, Peter Dreger, Jürgen Finke, MD, Guido Kobbe, MD, Uwe Platzbecker, Marie Robin, MD, Dietrich W. Beelen, Nicolaus Kroeger, MD

Blood (2019) 134 (Supplement_1): 1713.

https://doi.org/10.1182/blood-2019-121969

Published: 2019

Journal Articles

Cooperative Effects of a Dnmt Inhibitor and All- Trans Retinoic Acid in an AML Cell Line Model Lacking PML-Rara

Ruth Meier, Gabriele Greve, Christoph Niemöller, Heiko Becker, Tobias Ma, Ralitsa Langova, Björn Grüning, Lars Feuerbach, Daniel B. Lipka, Justus Duyster, Prof., Benedikt Brors, Christoph Plass, Michael Lübbert

Blood (2018) 132 (Supplement 1): 1359.

https://doi.org/10.1182/blood-2018-99-113450

Published: 2018

Journal Articles

Epigenetic regulation of NFE2 overexpression in myeloproliferative neoplasms

Jan C. Peeken, Jonas S. Jutzi, Julius Wehrle, Christoph Koellerer, Hans F. Staehle, Heiko Becker, Elias Schoenwandt, Thalia S. Seeger, Daniel H. Schanne, Monika Gothwal, Christopher J. Ott, Albert Gründer, Heike L. Pahl

Blood (2018) 131 (18): 2065–2073.

https://doi.org/10.1182/blood-2017-10-810622

Published: 2018

Includes: Supplemental data

Journal Articles

The Impact of Cytogenetic Clonality on Outcomes in Younger Acute Myeloid Leukemia Patients: Results on 1290 Patients Included in the EORTC/Gimema AML-10 and AML-12 Trials

Blood (2017) 130 (Supplement 1): 1385.

https://doi.org/10.1182/blood.V130.Suppl_1.1385.1385

Published: 2017

Journal Articles

Fetal Hemoglobin (HbF) Induction during Initial Decitabine (DAC) Treatment of Elderly High-Risk MDS and AML Patients: A Potential Dynamic Biomarker for Outcome

Julia Stomper, Gabriele Ihorst, Stefan Suciu, Philipp Nikolaus Sander, Heiko Becker, P.W. Wijermans, Emmanuel Bissé, Rainer Claus, Michael Lübbert

Blood (2017) 130 (Supplement 1): 4261.

https://doi.org/10.1182/blood.V130.Suppl_1.4261.4261

Published: 2017

Journal Articles

Phase I/II Study on Cytarabine and Idarubicin Combined with Escalating Doses of Clofarabine in Untreated Patients with Acute Myeloid Leukemia and High Risk for Induction Failure (AMLSG 17-10 CIARA)

Blood (2016) 128 (22): 4038.

https://doi.org/10.1182/blood.V128.22.4038.4038

Published: 2016

Journal Articles

Identification of a Novel Chromosomal Translocation t(11;16)(q23;q22) Fusing MLL to Enhancer of mRNA Decapping (EDC)-4 in Smoldering Acute Myeloid Leukemia

Heiko Becker, MD, Keisuke Kataoka, MD PhD, Gabriele Greve, Jesús Duque Afonso, MD, Tobias Ma, Sabine Bleul, Milena Pantic, PhD, Julia Schüler, DVM, PhD, Justus Duyster, MD, Michael L Cleary, MD, Seishi Ogawa, MD PhD, Michael Lübbert, MD

Blood (2016) 128 (22): 1696.

https://doi.org/10.1182/blood.V128.22.1696.1696

Published: 2016

Journal Articles

Elevated Pre-Treatment Fetal Hemoglobin Predicts Better Outcome in MDS/AML Patients Receiving 5-Aza-2'-Deoxycytidine (DAC)

Rainer Claus, MD, Gabriele Ihorst, PhD, Philipp Sander, Ljudmila Bogatyreva, Heiko Becker, MD, Pierre W Wijermans, MD, Stefan Suciu, Emmanuel Bissé, MD PhD, Michael Lübbert, MD

Blood (2016) 128 (22): 3175.

https://doi.org/10.1182/blood.V128.22.3175.3175

Published: 2016

Journal Articles

Single Cell Genotyping of Inv(16) AML in CBL Mutated Clonal Hematopoiesis Characterizes Clonal Architecture and Evolution of Exome Sequencing-Identified Mutations in the Protein Tyrosine Phosphatase Ptprt and Other Genes

Christoph Niemöller, Sabine Bleul, Nadja Blagitko-Dorfs, PhD, Christine Greil, MD, Kenichi Yoshida, MD PhD, Rainer Claus, MD, Dietmar Pfeifer, PhD, Seishi Ogawa, MD PhD, Michael Lübbert, MD, Heiko Becker, MD

Blood (2015) 126 (23): 3834.

https://doi.org/10.1182/blood.V126.23.3834.3834

Published: 2015

Journal Articles

Recurrent ETNK1 mutations in atypical chronic myeloid leukemia

Blood (2015) 125 (3): 499–503.

https://doi.org/10.1182/blood-2014-06-579466

Published: 2015

Includes: Supplemental data

NARROW

Intraindividual Comparison of Recognition of Symptom Burden in MPN between Patient- and Physician-Reported Assessment and Its Impact on Survival - an Analysis By the German Study Group for MPN (GSG-MPN)

Firstline Treatment with Ruxolitinib Versus Best Available Therapy in Patients with Polycythemia Vera: Pre-Specified Interim Analysis of the Randomized Phase 2b Ruxobeat Clinical Trial of the German Study Group for Myeloproliferative Neoplasms (GSG-MPN)

Decider-2: Prospective Randomized Multicenter Phase III Trial of Decitabine and Venetoclax Administered in Combination with All- Trans Retinoic Acid (ATRA) or Placebo in Patients with Acute Myeloid Leukemia Who Are Ineligible for Induction Chemotherapy

Single-Center Experience of Decitabine/Venetoclax in Newly Diagnosed Older AML Patients with Non-Favorable Genetics: Bridging to Allo-HCT or Treatment Continuation

Siremadlin, a Human Double Minute-2 (HDM2) Inhibitor, Added to Ruxolitinib after Suboptimal Response to Ruxolitinib Alone in Patients with Myelofibrosis: Results from Part 1 of the Phase 1/2 Adore Study

Genetic and Epigenetic Changes at Secondary Resistance after Continued Treatment in the Randomized Phase II Study of All- Trans Retinoic Acid (ATRA) and/or Valproic Acid (VPA) Added to Decitabine (DAC) in Newly Diagnosed Elderly AML Patients (DECIDER Trial)

All- Trans retinoic Acid Enhances the Antileukemic Activity of Decitabine and Venetoclax in Non-M3 AML Cells

Ruxolitinib Versus Best Available Therapy in Patients with Essential Thrombocythemia: Pre-Specified Interim Analysis of the Randomized Phase 2b Ruxobeat Clinical Trial of the German Study Group for Myeloproliferative Neoplasms (GSG-MPN)

Randomized Phase II Study of All- Trans Retinoic Acid and Valproic Acid Added to Decitabine in Newly Diagnosed Elderly AML Patients (DECIDER trial): Predictive Impact of TP53 Status

Activity of Decitabine (DAC) Combined with All-Trans Retinoic Acid (ATRA) in Oligoblastic AML: Subgroup Analysis of a Randomized 2x2 Phase II Trial

Clinical Relevance of Somatic Mutations in Chronic Myelomonocytic Leukemia Undergoing Allogeneic Stem Cell Transplantation

Cooperative Effects of a Dnmt Inhibitor and All- Trans Retinoic Acid in an AML Cell Line Model Lacking PML-Rara

Epigenetic regulation of NFE2 overexpression in myeloproliferative neoplasms

The Impact of Cytogenetic Clonality on Outcomes in Younger Acute Myeloid Leukemia Patients: Results on 1290 Patients Included in the EORTC/Gimema AML-10 and AML-12 Trials

Fetal Hemoglobin (HbF) Induction during Initial Decitabine (DAC) Treatment of Elderly High-Risk MDS and AML Patients: A Potential Dynamic Biomarker for Outcome

Phase I/II Study on Cytarabine and Idarubicin Combined with Escalating Doses of Clofarabine in Untreated Patients with Acute Myeloid Leukemia and High Risk for Induction Failure (AMLSG 17-10 CIARA)

Identification of a Novel Chromosomal Translocation t(11;16)(q23;q22) Fusing MLL to Enhancer of mRNA Decapping (EDC)-4 in Smoldering Acute Myeloid Leukemia

Elevated Pre-Treatment Fetal Hemoglobin Predicts Better Outcome in MDS/AML Patients Receiving 5-Aza-2'-Deoxycytidine (DAC)

Single Cell Genotyping of Inv(16) AML in CBL Mutated Clonal Hematopoiesis Characterizes Clonal Architecture and Evolution of Exome Sequencing-Identified Mutations in the Protein Tyrosine Phosphatase Ptprt and Other Genes

Recurrent ETNK1 mutations in atypical chronic myeloid leukemia

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only